Modern therapeutic potential of super-selective β<sup>1</sup>-adrenoblocker nebivolol

Beta-adrenoblockers, included in any cardiovascular disease treatment standard, became a key part of clinical practice only in late XX century. Nebivolol is a highly selective beta-1 -adrenoiblocker, modulating endothelial NO release and subsequent physiological vasodilatation. Nebivolol has multipl...

Full description

Saved in:
Bibliographic Details
Main Authors: V. I. Makolkin, D. A. Napalkov
Format: Article
Language:Russian
Published: «SILICEA-POLIGRAF» LLC 1970-01-01
Series:Кардиоваскулярная терапия и профилактика
Subjects:
Online Access:https://cardiovascular.elpub.ru/jour/article/view/1799
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849342018025684992
author V. I. Makolkin
D. A. Napalkov
author_facet V. I. Makolkin
D. A. Napalkov
author_sort V. I. Makolkin
collection DOAJ
description Beta-adrenoblockers, included in any cardiovascular disease treatment standard, became a key part of clinical practice only in late XX century. Nebivolol is a highly selective beta-1 -adrenoiblocker, modulating endothelial NO release and subsequent physiological vasodilatation. Nebivolol has multiple clinical indications, including coronary heart disease, arterial hypertension, and chronic heart failure. Due to its super-selectivity it can also be beneficial in patients with diabetes mellitus, chronic obstructive pulmonary disease, and erectile dysfunction.
format Article
id doaj-art-e7a9f5ec70b549fcbc0e8ef4bb3f233c
institution Kabale University
issn 1728-8800
2619-0125
language Russian
publishDate 1970-01-01
publisher «SILICEA-POLIGRAF» LLC
record_format Article
series Кардиоваскулярная терапия и профилактика
spelling doaj-art-e7a9f5ec70b549fcbc0e8ef4bb3f233c2025-08-20T03:43:30Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01251970-01-01581091161514Modern therapeutic potential of super-selective β<sup>1</sup>-adrenoblocker nebivololV. I. Makolkin0D. A. Napalkov1I.M. Sechenov Moscow Medical Academy. MoscowI.M. Sechenov Moscow Medical Academy. MoscowBeta-adrenoblockers, included in any cardiovascular disease treatment standard, became a key part of clinical practice only in late XX century. Nebivolol is a highly selective beta-1 -adrenoiblocker, modulating endothelial NO release and subsequent physiological vasodilatation. Nebivolol has multiple clinical indications, including coronary heart disease, arterial hypertension, and chronic heart failure. Due to its super-selectivity it can also be beneficial in patients with diabetes mellitus, chronic obstructive pulmonary disease, and erectile dysfunction.https://cardiovascular.elpub.ru/jour/article/view/1799β-adrenoblockersnebivololcoronary heart diseasearterial hypertensionheart failure
spellingShingle V. I. Makolkin
D. A. Napalkov
Modern therapeutic potential of super-selective β<sup>1</sup>-adrenoblocker nebivolol
Кардиоваскулярная терапия и профилактика
β-adrenoblockers
nebivolol
coronary heart disease
arterial hypertension
heart failure
title Modern therapeutic potential of super-selective β<sup>1</sup>-adrenoblocker nebivolol
title_full Modern therapeutic potential of super-selective β<sup>1</sup>-adrenoblocker nebivolol
title_fullStr Modern therapeutic potential of super-selective β<sup>1</sup>-adrenoblocker nebivolol
title_full_unstemmed Modern therapeutic potential of super-selective β<sup>1</sup>-adrenoblocker nebivolol
title_short Modern therapeutic potential of super-selective β<sup>1</sup>-adrenoblocker nebivolol
title_sort modern therapeutic potential of super selective β sup 1 sup adrenoblocker nebivolol
topic β-adrenoblockers
nebivolol
coronary heart disease
arterial hypertension
heart failure
url https://cardiovascular.elpub.ru/jour/article/view/1799
work_keys_str_mv AT vimakolkin moderntherapeuticpotentialofsuperselectivebsup1supadrenoblockernebivolol
AT danapalkov moderntherapeuticpotentialofsuperselectivebsup1supadrenoblockernebivolol